GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Float Percentage Of Total Shares Outstanding

Halberd (Halberd) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 17, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Halberd's float shares is 0.00 Mil. Halberd's total shares outstanding is 635.87 Mil. Halberd's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Halberd's Insider Ownership is 75.60%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Halberd's Institutional Ownership is 0.00%.


Halberd Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Halberd's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/635.87
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Halberd (Halberd) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236